Skip to main content

Select Drug Profiles

ASH 2019 - Chronic Lymphocytic Leukemia
Pooled Analysis of Ibrutinib versus Prior Regimen in Relapsed/Refractory Mantle-Cell Lymphoma with up to 7.5 Years of Extended Follow-Up
Read More
ASH 2019 - Chronic Lymphocytic Leukemia
Alliance A041702 Phase 3 Study Comparing Ibrutinib + Obinutuzumab versus Ibrutinib + Venetoclax + Obinutuzumab in Untreated, Older Patients with CLL
Read More
ASH 2019 - Chronic Lymphocytic Leukemia
Ixazomib, Rituximab, and Dexamethasone in Patients with Relapsed or Progressive Waldenström Macroglobulinemia
Read More
ASH 2019 - Chronic Lymphocytic Leukemia
Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab for First-Line Treatment of CLL with IGHV Mutation and without Del(17p)/Mutated TP53
Read More
Original Research, Practice Management
The Economic Implications of Hyperkalemia in a Medicaid Managed Care Population
Nihar R. Desai, MD, MPH, Pamala Reed, DrPH, MPH, Paula J. Alvarez, RPh, MBA, MPH, Jeanene Fogli, PhD, RD, Steven D. Woods, PharmD, Mary Kay Owens, RPh, CPh
Nihar R. Desai, MD, MPH; Pamala Reed, DrPH, MPH; Paula J. Alvarez, RPh, MBA, MPH; Jeanene Fogli, PhD, RD; Steven D. Woods, PharmD; Mary Kay Owens, RPh, CPh
Stakeholder Perspective
The Impact of Quality Care on a Medicaid Population with Hyperkalemia
Byron C. Scott, MD, MBA
by Byron C. Scott, MD, MBA
Read More
FDA Approvals
FDA Oncology Update
Read More
Perspectives
Predicting Success in Population Health
David B. Nash, MD, MBA
David B. Nash, MD, MBA
Read More
Original Research, Practice Management
Realized and Projected Cost-Savings from the Introduction of Generic Imatinib Through Formulary Management in Patients with Chronic Myelogenous Leukemia
David Campbell, PharmD, MS, Marlo Blazer, PharmD, BCOP, Lisa M. Bloudek, PharmD, MS, John Brokars, MS, Dinara Makenbaeva, MD, MBA
David Campbell, PharmD, MS; Marlo Blazer, PharmD, BCOP; Lisa Bloudek, PharmD, MS; John Brokars, MS; Dinara Makenbaeva, MD, MBA
Stakeholder Perspective
The Challenges in Budgeting Potential Savings with the Launch of Generic Drugs
James T. Kenney, RPh, MBA
by James T. Kenney, RPh, MBA
Read More
Practice Management
Key Trends in Healthcare for 2020 and Beyond
F. Randy Vogenberg, PhD, FASHP, John Santilli, MBA
F. Randy Vogenberg, PhD; John Santilli, MBA
Read More
ASH 2019 - Chronic Lymphocytic Leukemia
Ibrutinib + Rituximab versus FCR in Younger Patients with CLL: Extended Follow-Up of E1912 Trial
Read More
Page 43 of 244
Results 421 - 430 of 2434